Entrada Therapeutics, Inc. (TRDA) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE DESIGN CENTER PLACE
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:188,700291,064
Cash and cash equivalents45,157291,064
Other undisclosed cash, cash equivalents, and short-term investments143,543 
Debt securities, available-for-sale, accrued interest, after allowance for credit loss  
Debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss 142,170 
Other undisclosed current assets(120,995)7,636
Total current assets:209,875298,700
Noncurrent Assets
Operating lease, right-of-use asset25,340 
Property, plant and equipment7,6816,261
Restricted cash and investments3,950 
Other noncurrent assets5,210872
Total noncurrent assets:42,1817,133
TOTAL ASSETS:252,056305,833
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,5666,719
Accounts payable5,990706
Accrued liabilities7,5766,013
Deferred revenue  
Other undisclosed current liabilities8,406 
Total current liabilities:21,9726,719
Noncurrent Liabilities
Liabilities, other than long-term debt17,530396
Deferred rent credit  396
Operating lease, liability17,530 
Other undisclosed noncurrent liabilities  
Total noncurrent liabilities:17,530396
Total liabilities:39,5027,115
Equity
Equity, attributable to parent212,554298,718
Common stock33
Additional paid in capital402,893392,384
Accumulated other comprehensive loss(2,057) 
Accumulated deficit(188,285)(93,669)
Total equity:212,554298,718
TOTAL LIABILITIES AND EQUITY:252,056305,833

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues  
Gross profit:  
Operating expenses(97,248)(51,127)
Operating loss:(97,248)(51,127)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2,632(31)
Loss from continuing operations:(94,616)(51,158)
Loss before gain (loss) on sale of properties:(51,158)
Net loss available to common stockholders, diluted:(94,616)(51,158)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(94,616)(51,158)
Comprehensive loss:(94,616)(51,158)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,057) 
Comprehensive loss, net of tax, attributable to parent:(96,673)(51,158)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: